23andMe Holding Co. (ME) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates several concerns: a 12% revenue decrease, a significant cash position decline, and a going concern disclosure. Although cost-cutting measures are in place, the company is discontinuing therapeutic programs and reducing its workforce by 40%, which suggests financial strain. The Q&A section reveals a focus on restructuring and compliance, but lacks specific recovery timelines. The absence of a shareholder return plan and competitive pressures further contribute to a negative outlook, likely resulting in a stock price decrease of -2% to -8% over the next two weeks.
Key Financial Performance
Revenue $44 million, a decrease of approximately 12% year-over-year due to lower consumer services revenue, driven mainly by lower PGS kit sales volume and telehealth orders, as well as lower research services revenue as the GSK collaboration exclusive discovery term concluded in July 2023.
Gross Profit $22 million, representing a 3% increase year-over-year, driven primarily by growth in high-margin membership services, which more than offset the lower consumer and research services revenue.
Operating Expenses $84 million, a decrease from $101 million year-over-year, driven by lower personnel-related expenses, including noncash stock-based compensation expenses following workforce reductions and lower therapeutics-related R&D spend.
Net Loss $59 million, improved from a net loss of $75 million year-over-year, driven mainly by savings in operating expenses.
Adjusted EBITDA Loss of $33 million, improved from a loss of $45 million year-over-year, primarily due to lower R&D and personnel-related expenses and improvements in consumer services gross profit.
Cash and Cash Equivalents $127 million, down from $216 million as of March 31, 2024, indicating a need for additional liquidity to fund necessary expenditures and financial commitments.
Annualized Cost Savings from Restructuring Expected to be at least $35 million per year, with approximately $12 million in costs related to one-time severance, transition, and termination-related costs.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Total Health Membership Service: Launched a comprehensive longevity platform combining advanced exome sequencing, lab tests, and guidance from genetics-trained clinicians.
Weight Management Initiatives: Launched a study on genetics impacting GLP-1 efficacy and a genetic report on emotional eating for 23andMe+ Premium subscribers.
GLP-1 Weight Loss Telehealth Membership: Introduced on the Lemonaid Health platform for convenient access to semaglutide medications.
AI Assistant DaNA: Launched for 23andMe+ Premium customers to assist in understanding ancestry and health reports.
Market Expansion in Membership Services: Increased revenue from membership services, with over 21% of total revenue in Q2 compared to 9% in the prior year.
Ancestry Composition Features: Improved features with new regions and historical matches, enhancing customer engagement.
Business Restructuring: Undertaking restructuring to streamline operations, reduce costs, and discontinue therapeutic programs.
Workforce Reduction: Reducing workforce by approximately 40% to improve financial sustainability.
Cost Savings from Restructuring: Expected annualized cost savings of at least $35 million.
Board of Directors Reconstitution: Reconstituted Board with 3 new independent directors to enhance governance.
Focus Shift from Therapeutics: Winding down therapeutics division while exploring strategic alternatives for the pipeline.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Business Restructuring: 23andMe is undertaking a business restructuring to streamline operations, reduce costs, and position the company for long-term success. This includes discontinuing all therapeutic programs and reducing the workforce by approximately 40%.
Financial Performance: Revenue for Q2 was $44 million, a decrease of approximately 12% compared to the prior year, primarily due to lower consumer services revenue and the conclusion of the GSK collaboration.
Going Concern Disclosure: The financial statements include a going concern disclosure, indicating the company will need additional liquidity to fund necessary expenditures and financial commitments for the next 12 months.
Cost-Cutting Measures: The company is implementing cost-cutting measures and expects annualized cost savings of at least $35 million per year, with an estimated $12 million in one-time costs related to severance and transition.
Competitive Pressures: The company faces competitive pressures in the consumer genetics and telehealth markets, which may impact revenue and market share.
Regulatory Issues: As a public company, 23andMe must comply with various regulatory requirements, which can pose challenges and impact operational flexibility.
Supply Chain Challenges: The company has experienced challenges related to supply chain disruptions, affecting the availability of PGS kits and telehealth services.
Economic Factors: Economic conditions may influence consumer spending on genetic testing and health services, potentially impacting revenue.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Business Restructuring: 23andMe is undertaking a business restructuring to streamline operations, reduce costs, and position the company for long-term success. This includes discontinuing all therapeutic programs and reducing the workforce by approximately 40%.
Strategic Alternatives for Therapeutics: The company will explore strategic alternatives for its therapeutics pipeline to enable continued development outside of 23andMe.
Focus on Preventive Health: 23andMe aims to become a sustainable cash flow positive company by leveraging its platform to deliver integrated preventive health services and genetic insights.
Weight Management Initiatives: The company launched several weight management initiatives, including a study on genetics impacting GLP-1 efficacy and a telehealth membership for weight loss.
Recurring Revenue Growth: 23andMe doubled the percentage of recurring revenue, achieving over 21% of total revenue in Q2, up from 9% in the prior year.
Revenue Expectations: Revenue for Q2 was $44 million, a decrease of approximately 12% year-over-year, primarily due to lower consumer services revenue.
Cost Savings from Restructuring: The restructuring is expected to yield annualized cost savings of at least $35 million, with an estimated $12 million in one-time costs related to severance and transition.
Cash Position: The company ended the quarter with cash and cash equivalents of $127 million, down from $216 million, indicating a need for additional liquidity.
Future Financial Outlook: 23andMe is focused on improving its financial condition and liquidity position to extend its cash runway, while managing operational expenses and considering raising additional capital.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: The company is working to improve its financial condition and liquidity position, which may include raising additional capital. However, no specific share buyback program or dividend program was mentioned in the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the plan for recovery?
A:Regaining compliance was a top priority, achieved with a new Board and a reverse stock split. Sustainability is also a focus, with plans to deprioritize therapeutics, cut expenses, and grow the business through subscriptions and database opportunities.
Q:Why was the 120 reverse stock split necessary?
A:The reverse stock split was necessary to regain compliance with NASDAQ listing requirements for a minimum bid price of $1 per share.
Q:What steps are being taken to make the business profitable?
A:Prioritizing subscription products for recurring revenue, growing research partnerships, and reducing costs through restructuring and pausing therapeutic assets.
Q:What goals are you looking to complete in 2025?
A:Focus on growing subscriptions, developing the database business for clinical trials, and out-licensing therapeutic programs.
Q:Review of Unclear Management Responses
A:No direct answers were avoided, but some responses lacked specific details on the timeline for recovery and profitability measures.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BMI
Health
Medieval
Watson Vice
andMe Premium
andMe path
area subscription
bid price
cell
collaboration pharmaceutical
compliance NASDAQ
compliance priority
concern disclosure
condition liquidity
cost saving
development andMe
improvement
industry
liquidity position
listing
match
membership service
mission
path future
prevention longevity
product value
rate
requirement andMe
restructuring
stock split
subscription product
value subscription
weight
yesterday
ME Transcript
23andMe Holding Co. (ME) Q2 2025 Earnings Call Transcript
Unknown11-12
The earnings call indicates several concerns: a 12% revenue decrease, a significant cash position decline, and a going concern disclosure. Although cost-cutting measures are in place, the company is discontinuing therapeutic programs and reducing its workforce by 40%, which suggests financial strain. The Q&A section reveals a focus on restructuring and compliance, but lacks specific recovery timelines. The absence of a shareholder return plan and competitive pressures further contribute to a negative outlook, likely resulting in a stock price decrease of -2% to -8% over the next two weeks.
23andMe Holding Co. (ME) Q1 2025 Earnings Call Transcript
Neutral8-9
23andMe Holding Co. (ME) Q3 2024 Earnings Call Transcript
Neutral2-8
23andMe Holding Co. (ME) Q2 2024 Earnings Call Transcript
Unknown11-9
The earnings call reveals a widening EBITDA deficit and a significant decrease in cash reserves, indicating financial strain. Despite some positive developments like the GSK partnership and promising trial results, the lack of transparency around costs and the cybersecurity incident may cause investor concern. The focus on subscription models and market expansion is positive, but the financial health and guidance uncertainty suggest a negative stock reaction.
ME Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
